Press Release April 06, 2021
View PDF

Goodwin Expands West Coast Platform With Life Sciences Partners Can Cui And Steven Green

高赢欢迎合伙人崔粲和Steven Green加盟以进一步扩展高赢西海岸的生命科学业务平台

Global law firm Goodwin today announced that Dr. Can Cui and Steven Green joined the firm’s Life Sciences practice as partners, resident in the San Francisco and Silicon Valley offices, respectively.

“We are thrilled to expand our California team as we continue to build a global destination practice for innovative life sciences companies and investors,” said Mitchell Bloom, chair of Goodwin’s Life Sciences practice. “Can and Steven are incredibly strong, multitalented lawyers who strengthen our fully integrated team of lawyers across our IP, licensing, collaborations, regulatory, and corporate practices, and reinforce our holistic approach to our ‘one-stop shop’ lifecycle practice.”

Dr. Cui serves as an external general counsel to life sciences companies in both the U.S. and China. His practice focuses on China-related life sciences transactions, including cross-border licensing, collaboration, and strategic partnerships, and M&A, and joint ventures. He has a successful track record of representing both licensors and licensees in U.S.–China licensing transactions and regularly represents life sciences companies and investors in intellectual property due diligence and Chinese regulatory matters. As a former scientist, he has strong research experience in both immune-oncology and virology, and holds a doctorate in biological chemistry and molecular pharmacology from Harvard University.

“The U.S. and China are the two largest life sciences markets in the world, and Goodwin’s comprehensive global offering adds significant value to companies operating in both markets,” said Dr. Cui. “I’m thrilled to join the firm's talented, collaborative team to deliver exceptional service to clients.”

Mr. Green advises emerging life sciences and technology companies on a full spectrum of business and legal issues throughout their corporate lifecycles. He has extensive experience advising clients on new company formations, fundraisings, mergers and acquisitions, and initial public offerings. Mr. Green also advises venture capital firms on structuring and executing investments into life sciences and technology companies.

“Goodwin’s seamless integration of its market-leading multidisciplinary life sciences platform allows the firm to provide the best possible service to clients,” said Mr. Green. “I’m excited to be a part of a firm with an incredible culture and commitment to further expand its capabilities in California and beyond.”

U.S. News — Best Lawyers’ 2021 edition named Goodwin the Biotechnology Law Firm of the Year for the sixth time. LMG Life Sciences also named Goodwin firm of the year for 2020 in the corporate, lifecycle, and intellectual property categories. Mergermarket’s Deal Drivers FY 20 reports named Goodwin the number one firm (by deal count) for Pharma, Medical, and Biotech M&A in North America and the number two firm (by value) for Pharma, Medical, and Biotech M&A in Europe, the Middle East, and Africa. Chambers UK 2021 recognized Goodwin’s Life Sciences UK practice for the first time in 2020 and The British Legal Awards named Goodwin’s UK team the Life Sciences Team of the Year in 2020.

Goodwin’s Life Sciences practice represents leading public and private life sciences companies and investors across their entire life cycles — including financings, capital market transactions, M&A, collaborations and licensing, intellectual property, and regulatory matters.

全球性律师事务所高赢国际律师事务所(高赢)今天宣布,崔粲博士和Steven Green师已作为生命科学业务部合伙人加盟该事务所,并分别常驻旧金山市和硅谷办事处。

赢生命科学业务部主管Mitchell Bloom说:在我们持续为创新型生命科学公司和投资者建立一个全球业务平台的过程中,我们很高兴进一步扩大我们的加州团队。崔粲和Steven均是非常优秀而且多才多艺的律师,他们的加盟在知识产权、许可、合作、监管和公司法方面强化了我们全面整合的律师团队,并加强了我们的全生命周期一站式综合服务。

崔博士担任美国和中国生命科学公司的外部总法律顾问,其业务专注于与中国相关的生命科学交易,包括跨境技术许可、合作和战略伙伴协议,以及并购和合资等交易。崔博士在中美生命科学许可交易中代理许可方和被许可方均有丰富的成功经验,并经常代表生命科学公司和投资者处理知识产权尽职调查和中国监管事务。崔博士之前是一名科学家,在免疫肿瘤学和病毒学方面均有深厚的研究经验,并拥有哈佛大学生物化学与分子药理学博士学位。

崔博士说:美国和中国是世界上最大的两个生命科学市场,高赢的综合性全球服务能为在这两个市场运营的公司创造巨大价值。我很高兴能加入这个具有合作精神的优秀人才团队,为客户提供卓越的服务。

Green师专注于向新兴的生命科学和技术公司在其全生命周期内的各个环节事务提供全方位的业务支持和法律咨询服务。他在为客户组建新公司、进行募资、并购和首次公开发行(IPO)方面拥有丰富的经验。Green师也为风险投资公司构建和执行对生命科学和技术公司的投资。

Green师说:赢的无缝结合和市场领先的多元生命科学平台,使其能够为客户提供最佳的服务。我很高兴能成为高赢的一员,因为高赢有著卓越的文化,并致力于扩展其在加州以及其他地方的业务能力。 

2021年《美国新闻最佳律师》(U.S. News — Best Lawyers)第六次将高赢评为年度最佳生物技术律师事务所。2020LMG Life Sciences还将高赢评为公司法、生命周期和知识产权类别的年度最佳律师事务所。Mergermarket2020财年交易驱动因素报告将高赢评为北美制药、医疗和生物技术并购最活跃的律师事务所(按交易量计),以及欧洲、中东和非洲制药、医疗和生物技术并购的第二最活跃律师事务所(按交易价值计)。2021年《钱伯斯英国》在2020年首次认可了高赢在英国的生命科学业务,而The British Legal Awards将高赢的英国团队评为2020年年度最佳生命科学团队。

赢的生命科学业务部为多家上市及私人生命科学公司和投资者处理其生命周期内的各个环节事务,包括融资、资本市场交易、并购、合作与许可协议、知识产权和合规监管